Abacus Health Products CEO Perry Antelman and Rob Gronkowski to Present at Cowen’s 2nd Annual Boston Cannabis Conference

WOONSOCKET, R.I. & TORONTO–(BUSINESS WIRE)–$ABAHF #AbacusHealthProducts–Abacus Health Products, Inc. (CSE:ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced that it will participate in the 2^nd Annual Boston Cannabis Conference presented by Cowen. The event will be held November 11^th – 13^th 2019 at The Intercontinental Hotel in Boston, MA.

Abacus’ CEO Perry Antelman will participate in a panel discussion on CBD alongside other leading CBD companies. Abacus has also confirmed Cowen CEO Jeffrey Solomon will sit down with Rob Gronkowski for a fireside chat that will highlight Abacus’ recent partnership with the three-time football world champion. Abacus will be available for 1-on-1 meetings throughout the conference.

About Abacus Health Products, Inc.

Abacus is engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: CBD CLINIC™, marketed to the professional practitioner market, and CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

To learn more about Abacus, visit www.abacushp.com

Contacts

For further information:

Hank Hague, Chief Financial Officer

Email: [email protected]
Or

Bill Mitoulas, Investor Relations

Email: [email protected]
Office: 1.416.479.9547